Ignacio Muñoz-Sanjuan: “Podríamos ver una terapia para la enfermedad de Huntington aprobada en 2026. Es un día para la esperanza: aunque al principio el tratamiento será limitado, el acceso aumentará en los próximos años.”
24/09/2025 Ignacio Muñoz-Sanjuan, neuroscientist and founder of the non-profit Factor-H, has expressed optimism that an experimental gene therapy for Huntington’s disease, developed by uniQure and called AMT-130, could receive regulatory approval in the first half of 2026, in what is a very significant milestone for patients and families affected by the disorder. “It is a […]
English 
Español 
Português do Brasil